pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
HORIZON · news · pharmadog
← back to HORIZON
News mentioning HORIZON
51
stories
9h
Immutep, Molecular cut workforces
biospace
8d
STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?
stat
17d
Rudy Tanzi has long wanted to prevent Alzheimer's. He may be close
endpoints
18d
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
25d
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
Sep 30, 26
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
biopharma dive
Sep 30, 26
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
fiercebiotech
Sep 30, 26
No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reins
biospace
Sep 24, 26
Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution
stat
Sep 23, 26
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study
biospace
Sep 23, 26
Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
biospace
Sep 22, 26
Amgen reports a Phase 3 win with Sjögren’s drug candidate
biopharma dive
Sep 22, 26
Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal
endpoints
Sep 22, 26
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
fiercebiotech
Sep 16, 26
5 biotechs braving the commercial waters with product launches
biospace
Sep 15, 26
Exercise — and echocardiograms — in space protected astronauts’ hearts in study
stat
Sep 14, 26
The GOP’s $50 billion rural health fund is coming up short, hospital leaders say
stat
Sep 10, 26
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
biopharma dive
Sep 8, 26
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
Sep 8, 26
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
biospace
Sep 4, 26
STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
stat
Sep 4, 26
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
fiercebiotech
Sep 2, 26
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
biospace
Aug 26, 26
Inside the Gulf biotech deal model, ahead of RGMBS 2026 in Riyadh
biospace
Aug 11, 26
Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths
stat
Jul 31, 26
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
biospace
Jul 30, 26
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
Jul 30, 26
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
Jul 29, 26
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
Jul 28, 26
An eye drug biotech banks $118M and stocks its executive suite
biopharma dive
← prev
page 1 of 2
next →
